bluebird bio Completes Q2 2024 Form 10-Q Filing, Strengthens Gene Therapy Leadership

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) has successfully completed the filing of its Form 10-Q for the quarter ending June 30, 2024, with the Securities and Exchange Commission (SEC). This filing ensures that the company remains up-to-date with its SEC periodic reporting obligations.

About bluebird bio, Inc.

bluebird bio is at the forefront of developing curative gene therapies, aiming to provide patients and their families with more "bluebird days." Established in 2010, the company has been a trailblazer in the gene therapy sector, transitioning from a scientific pioneer to a commercial leader. bluebird bio has achieved FDA approvals for three therapies in less than two years, showcasing its ability to translate clinical research into real-world applications.

Focused on severe genetic diseases, bluebird bio boasts the largest and most comprehensive ex-vivo gene therapy dataset in the industry. Their leading programs target conditions such as sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Each therapy is meticulously crafted to address the root cause of the disease, supported by advanced analytical methods to ensure the safety and efficacy of their lentiviral vector technologies.

As a standalone commercial entity, bluebird bio is committed to advancing the field of gene therapy. The company leverages its extensive real-world experience and maintains a strong dedication to patient communities. This commitment is reflected in its people-centric culture, which attracts and nurtures a diverse and dedicated team. bluebird bio continues to innovate and expand its impact in the gene therapy landscape, providing innovative solutions for patients, healthcare providers, and payers alike.